News

All three countries have permission to sell commercial product from their local health authority for the treatment of patients with relapsed or refractory CD30-positive Hodgkin lymphoma (HL) and

ETI-204 is a potential target for future acquisition into the Strategic National Stockpile, the US government’s repository of critical medical supplies for biowarfare preparedness. ETI-204 is the only

This will give key stakeholders and the agency the opportunity to address any outstanding issues before the final policy is presented to the EMA’s management board for endorsement

German pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both

The FDA acceptance enables Stemline Therapeutics to advance SL-701 into a Phase II trial of adults with glioblastoma multiforme (GBM) in first recurrence. SL-701, a subcutaneously-administered cancer vaccine,

The company has started the launch preparation with its US distributor partner and will commence marketing the product as soon as the launch preparation is completed. According to

Aptiom, a voltage-gated sodium channel blocker, is a new chemical entity approved by the US Food and Drug Administration (FDA) in November 2013, and is available in four

Mersana’s conjugation technology includes its biodegradable Fleximer polymer and a broad array of customizable linker chemistries matched to its diverse, cytotoxic payloads. As part of the deal, Takeda

The deal, which is the first broad research collaboration between PatientsLikeMe and a pharmaceutical company, offers PatientsLikeMe the opportunity to expand its patient network in oncology. PatientsLikeMe co-founder